Minnesota State Legislation SF 2744 that appoints the Council to the advisory committee of the Prescription Drug Affordability Board

The development and availability of transformative treatments for rare diseases poses both an incredible opportunity and an enormous challenge for the state of Minnesota. RDAC inclusion on the PDAB ensures that rare disease drug development and research is not restricted nor held to the same standards as common diseases while at the same time sustainable reimbursement models that balance value and cost are considered.